On this page
How do you review a carton or container label for medication-error risks?
Review every actual presentation at its physical size, with the controlled text and intended use in view. Check prominent product identity, dosage form, strength, route and relevant warnings; then examine contrast, crowding, orientation and differentiation from adjacent products. Reconcile final artwork with the reviewed baseline. Correct text in a flat PDF does not by itself establish that a curved, folded or reflective package is readable.
Before you begin
Human prescription drug and biological product carton/container design, using the May 2022 FDA safety guidance. Product-specific labeling requirements and any small-container exceptions need their own assessment.
What you will prepare: A presentation-by-presentation artwork set and a documented identity, legibility and medication-error review.
Sections covered in this guide (2)
Collect the physical and textual baseline
Obtain the container dimensions, printable area, material, curvature, closure and carton layout. Identify every strength, fill volume, package size and route. Bring the controlled product name, concentration/strength expression, storage information and relevant cautionary statements into the artwork review. A text-only PDF cannot show whether a seam, fold or reflective material obscures a critical statement.
Review the actual user’s decision
FDA’s guidance emphasizes critical information on the principal display panel and medication-error risks. Review how the intended user identifies, selects, prepares and administers the product. Compare adjacent strengths and presentations side by side. Inspect contrast, crowding, orientation and whether key information can be read together. Do not invent a universal font-size pass criterion: the appropriate assessment depends on the package and applicable provisions. A small container is not a general permission to delete required information.
Move from draft to final with a change record
The draft artwork is the proposal for review; final artwork must be reconciled to the actual authorized baseline and applicable submission instructions. Record each agency comment, affected panel, revised version and verification result. Compare production-ready output with the reviewed artwork after typesetting. Escalate any changed wording, strength expression or warning; do not classify it as a cosmetic correction solely because the designer made it.
Fictional example: correct text, wrong visual hierarchy
Two strengths have correct text but nearly identical cartons, while a large product logo draws attention away from the strength. Record the selection risk, show the two presentations together and request a design revision. Repeat the review at actual size. If the product changes from a tablet carton to a curved vial label, reassess the readable field and viewing angles rather than reusing the carton’s pass result.
Review the package as the user encounters it
Start with the handling task: selecting the product, checking the strength, preparing it and administering it. Use the real dimensions and presentation relationships rather than reviewing each artwork file only as an enlarged image.
| Use task | Review material | Question to resolve |
|---|---|---|
| Identify | Actual principal display panel and surrounding graphics | Can the user find the product names and dosage form without a logo dominating them? |
| Select strength | Adjacent strengths and pack sizes together | Are strength and presentation differences clear without relying only on color? |
| Confirm route | Full panel layout and applicable route statements | Is the route clear where it is needed for safe identification? |
| Prepare | Package type, fill information and controlled instructions | Could concentration, total content or nearby text be misread as a dose? |
| Read under use conditions | Actual-size proof, curvature, material and intended orientation | Do seams, folds, glare or overprinting obscure critical information? |
| Release | Reviewed artwork, production output and change record | Has the approved working content or hierarchy changed during production? |
FDA's May 2022 guidance distinguishes color differentiation from color coding. Color can help draw attention to a strength difference, but users can perceive it differently, lighting can alter its appearance, and reliance on color can replace reading the label. Do not treat a new color palette as sufficient correction of a selection risk. Pair it with readable text and a clear hierarchy, and assess the actual presentation.
Fictional layout exercise: two tablet strengths have distinct numbers but the same dominant graphics. The larger number is partly obscured by a carton fold. Revise the layout and compare both physical proofs together. A screenshot at 200% magnification does not demonstrate that the issue is resolved at actual size. Record the changed panel, the observed reading task and the verification result.
The guidance also warns that a dosing-frequency statement placed immediately with the strength can look like a complete dosing instruction. Keep product strength distinct from a patient-specific or regimen-specific dose. This is a layout and meaning review, not an invitation for the designer to create administration instructions.
Identify which comments affect text and which affect its presentation. Moving a warning to a less visible surface can matter even when every word remains present. Likewise, a changed strength expression needs scientific and regulatory review even when the designer calls it a space-saving edit. Do not assign every production change the status “cosmetic.”
Reconcile the artwork with the draft text, labeling history and final package. A new container geometry or presentation reopens the relevant review; a prior carton decision does not automatically cover a vial.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is a different carton color enough to distinguish product strengths?
Not by itself. FDA’s guidance identifies limitations of color perception, lighting and reliance on color instead of reading. Review strength text, contrast and other visual distinctions together across the actual presentations. Color can support differentiation, but should not be the only evidence that selection risk is controlled.
Can enlarged artwork replace an actual-size package review?
An enlarged image can help inspect details, but it does not establish readability at the actual package size or show every effect of curvature, folds and material. Review the intended physical presentation and compare neighboring strengths. Record how the user can identify the critical information under the relevant conditions.
Should strength and dosing frequency be placed together as one prominent statement?
Assess the risk that the combination could be read as a complete dose instruction. FDA’s guidance cautions against locating a frequency statement with or immediately after the strength in that way. Preserve the distinction between product strength and the supported regimen rather than allowing layout to imply a new instruction.
Does a small container automatically permit omission of critical information?
No. Establish the product-specific requirements and any applicable exception with the responsible regulatory reviewer. A space constraint alone does not establish permission to delete information. Reassess layout, readable area and appropriate presentation while keeping the actual proposed omission and its basis explicit.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA: Container Labels and Carton Labeling Design ↗May 2022 final guidance; sections III–IV on medication-error risk, principal display panel and legibility. Cover and passages checked September 22, 2026.
Regulation
21 CFR 314.50: NDA content and labeling ↗Paragraphs (c)(2)(i), (e)(2) and (l). Current eCFR reopened October 6, 2026, displaying currency through October 2, 2026. Annotated proposed text and labeling copies are separate provisions.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.14.1.1. A heading identifies placement, not mandatory applicability.